NYSE:CC - Chemours Stock Price, Forecast & News

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours announced a quarterly dividend on Wednesday, October 30th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.25 per share on Monday, December 16th. This represents a $1.00 annualized dividend and a yield of 6.00%. The ex-dividend date is Thursday, November 14th. View Chemours' Dividend History.

Chemours Co (NYSE:CC) released its quarterly earnings data on Monday, November, 4th. The specialty chemicals company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.03. The specialty chemicals company had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a net margin of 7.24% and a return on equity of 58.38%. The firm's revenue for the quarter was down 14.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.49 EPS. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Chemours.

Chemours updated its FY19 earnings guidance on Monday, November, 4th. The company provided EPS guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47.

12 brokerages have issued 12-month price targets for Chemours' stock. Their forecasts range from $14.50 to $42.00. On average, they expect Chemours' share price to reach $23.15 in the next year. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Price Targets for Chemours.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

News articles about CC stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemours earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Chemours.

Chemours saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 16,370,000 shares, a drop of 5.9% from the December 15th total of 17,390,000 shares. Based on an average daily volume of 2,490,000 shares, the short-interest ratio is currently 6.6 days. Currently, 10.1% of the company's shares are short sold. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), W. R. Grace & Co (GRA), Ashland Global (ASH), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Ingevity (NGVT), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Johnson & Johnson (JNJ), DowDuPont (DWDP) and Pfizer (PFE).

Chemours' stock is owned by a variety of of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.40%), Heritage Investors Management Corp (0.08%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.02%), Boenning & Scattergood Inc. (0.01%) and Janney Montgomery Scott LLC (0.01%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc, Janney Montgomery Scott LLC, Boenning & Scattergood Inc., State of Alaska Department of Revenue and Heritage Investors Management Corp. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, DNB Asset Management AS and FNY Investment Advisers LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $16.66.

Chemours has a market capitalization of $2.72 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]